These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38014060)

  • 41. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
    Sattler M; Scheijen B; Weisberg E; Griffin JD
    Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Rare Case of p190 BCR-ABL Chronic Myeloid Leukemia With a Very Good Response to Tyrosine Kinase Inhibitors.
    Gandhe N; Vekaria M; Dabak V
    Cureus; 2021 Aug; 13(8):e16914. PubMed ID: 34513487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
    Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
    J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure of the Bcr-Abl oncoprotein oligomerization domain.
    Zhao X; Ghaffari S; Lodish H; Malashkevich VN; Kim PS
    Nat Struct Biol; 2002 Feb; 9(2):117-20. PubMed ID: 11780146
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
    McWhirter JR; Galasso DL; Wang JY
    Mol Cell Biol; 1993 Dec; 13(12):7587-95. PubMed ID: 8246975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias.
    van Denderen J; ten Hacken P; Berendes P; Zegers N; Boersma W; Grosveld G; van Ewijk W
    Leukemia; 1992 Nov; 6(11):1107-12. PubMed ID: 1434792
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cloning, expression, purification and functional characterization of the oligomerization domain of Bcr-Abl oncoprotein fused to the cytoplasmic transduction peptide.
    Huang SF; Liu DB; Zeng JM; Xiao Q; Luo M; Zhang WP; Tao K; Wen JP; Huang ZG; Feng WL
    Protein Expr Purif; 2009 Apr; 64(2):167-78. PubMed ID: 19041400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of BCR/ABL fusion proteins on the course of Ph leukemias.
    Telegeev GD; Dubrovska AN; Dybkov MV; Maliuta SS
    Acta Biochim Pol; 2004; 51(3):845-9. PubMed ID: 15448745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein.
    McWhirter JR; Wang JY
    Oncogene; 1997 Oct; 15(14):1625-34. PubMed ID: 9349495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
    Kurzrock R; Kantarjian HM; Druker BJ; Talpaz M
    Ann Intern Med; 2003 May; 138(10):819-30. PubMed ID: 12755554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
    Danisz K; Blasiak J
    Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
    Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
    Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
    El Rashedy AA; Olotu FA; Soliman MES
    Chem Biodivers; 2018 Mar; 15(3):e1700533. PubMed ID: 29325229
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
    MacPartlin M; Smith AM; Druker BJ; Honigberg LA; Deininger MW
    Leukemia; 2008 Jul; 22(7):1354-60. PubMed ID: 18548107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
    Williams RT; Sherr CJ
    Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.
    Thomas EK; Cancelas JA; Zheng Y; Williams DA
    Leukemia; 2008 May; 22(5):898-904. PubMed ID: 18354486
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
    Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV
    J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.